The present invention relates to the field of medicine. It relates more particularly to a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1 for use as a medicament. The product of the invention is preferably for use for preventing or treating cancer. The description further relates to vectors, cells, vehicles and compositions capable of delivering and expressing a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1, and to uses thereof.

The present invention relates to the field of medicine. It relates more particularly to a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1 for use as a medicament. The product of the invention is preferably for use for preventing or treating cancer. The description further relates to vectors, cells, vehicles and compositions capable of delivering and expressing a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1, and to uses thereof.

Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

Provided herein are Cyclic Nucleotide Phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.

The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT.sub.2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D.sub.1 and D.sub.2 receptor signaling system, and/or the μ-opioid receptor.

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.